The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026

From Hormone Insight (hormoneinsight.com)

Six stories this week that endocrinologists, diabetologists, and internists need to know.

TIMESTAMPS:

0:00 — Introduction & This Week's Stories

1:30 — Orforglipron (Foundayo) FDA Approval: The Oral GLP-1 Pill — Access-Changer, Not Game-Changer

7:00 — Semaglutide 7.2 mg (Wegovy HD): 21% Weight Loss, But Watch the Dysesthesia Signal

11:30 — Insulin Icodec (Awiqli): Once-Weekly Insulin — Sounds Great Until You Think About Sick Days

16:00 — SURPASS-CVOT Post-Hoc in JAMA Cardiology: Tirzepatide's Cardiorenal NNT of 27

19:30 — AACE 2026 Type 2 Diabetes Algorithm Update

21:30 — GLP-1 RAs in Parkinson's Disease: 5 RCTs, 708 Patients, No Signal

24:00 — Closing Thoughts

REFERENCES & SHOW NOTES:

▸ Orforglipron FDA approval: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

▸ Wegovy HD FDA approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

▸ Awiqli FDA approval: https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html

▸ Nissen SE et al. JAMA Cardiol 2026 — SURPASS-CVOT cardiorenal post-hoc: https://doi.org/10.1001/jamacardio.2026.0767

▸ Nicholls SJ et al. N Engl J Med 2025 — SURPASS-CVOT primary: https://doi.org/10.1056/NEJMoa2505928

▸ AACE 2026 T2D Algorithm: https://www.sciencedirect.com/science/article/pii/S1530891X26000224

▸ Raza H et al. Brain Behav 2026 — GLP-1 RAs in Parkinson's: https://doi.org/10.1002/brb3.71344

ABOUT THIS PODCAST:

A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.

▸ Website: https://hormoneinsight.com

▸ Full show notes: https://hormoneinsight.com/podcast

️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.

#Endocrinology #DiabetesResearch #GLP1 #Orforglipron #Foundayo #WegovyHD #Semaglutide #InsulinIcodec #Awiqli #Tirzepatide #SURPASSCVOT #ObesityMedicine #Type2Diabetes #ClinicalTrials #EvidenceBasedMedicine #MedicalPodcast #HormoneInsight #EndocrinologyPodcast #Diabetology #CME #MedTwitter #DoctorsOfYouTube #InternalMedicine #Cardiology #CardiometabolicHealth #WeeklyInsulin #OralGLP1 #ParkinsonsDisease #AACE #PhysicianEducation

In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care.

Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure

In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes.

For full paper, click here

Visit HormoneInsight

In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment.

For more: Semaglutide vs Canagliflozin for Type 2 Diabetes

To read the original paper

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.

For summary, click here.

Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027

In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP <120 mm Hg) significantly reduced cardiovascular events compared to standard treatment (systolic BP <140 mm Hg), though it was associated with increased risks of symptomatic hypotension and hyperkalemia.

Bi, Y., Li, M., Liu, Y., et al. (2024). “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” New England Journal of Medicine. doi:10.1056/NEJMoa2412006

For summary - click here.

This episode explores the potential of semaglutide, a once-weekly GLP-1 analog, in managing type 2 diabetes. We examines a groundbreaking study published in Diabetes Care which found that semaglutide effectively reduces HbA1c levels and promotes weight loss in patients. The episode breaks down the study's findings, highlighting the dose-dependent effects of semaglutide and strategies for managing potential side effects. Tune in for insights into this promising new treatment option.

Nauck, M.A., Petrie, J.R., Sesti, G. et al., 2016. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 39(2), pp.231–241.

https://doi.org/10.2337/dc15-0165